The main goal of cancer vaccines is to elicit a tumor-specific adaptive immune response by activating CD8+ cytotoxic T lymphocytes for tumor cell lysis and Th1 CD4+ T cells to enhance CTL activity [1,22,23]. This evidence concerns the gene CD4 and neoplasm.